Lantheus inks Mo-99 deal with MDS Nordion

Lantheus Medical Imaging has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m.

Under terms of the new agreement, Lantheus will begin receiving an additional supply of Mo-99 on a weekly basis once the National Research Universal reactor at Chalk River, Ontario, is back online, which is currently anticipated to be at the end of July.

The North Billerica, Mass.-based Lantheus said the contract is in place until July 31, 2011.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.